Skip to main content
PMC home page
Neurotherapeutics logoLink to Neurotherapeutics
. 2009 Oct;6(4):648–662. doi: 10.1016/j.nurt.2009.07.001

Targeting neuroprotection as an alternative approach to preventing and treating neuropathic pain

Thierry Bordet 1, Rebecca M Pruss 1,✉
PMCID: PMC5084287  PMID: 19789070

Summary

Neuropathic pain syndromes arise from dysfunction of the nerve itself, through traumatic or nontraumatic injury. Unlike acute pain syndromes, the pain is long-lasting and does not respond to common analgesic therapies. Drugs that disrupt nerve conduction and transmission or central sensitization, currently the only effective treatments, are only modestly effective for a portion of the patients suffering from neuropathic pain and come with the cost of serious adverse effects. Neurodegeneration, as a reaction to nerve trauma or chronic metabolic or chemical intoxication, appears to be an underlying cause of neuropathic pain. Identifying mechanisms of neurodegeneration and designing neuroprotective therapies is an ambitious goal toward treating or even preventing the development of these disabling disorders.

Key Words: Neuropathic pain, neurodegeneration, trophic factors, mitochondria

References

  • 1.Cata JP, Weng HR, Lee BN, Reuben JM, Dougherty PM. Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol. 2006;72:151–169. [PubMed] [Google Scholar]
  • 2.Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006;29:1518–1522. doi: 10.2337/dc05-2228. [DOI] [PubMed] [Google Scholar]
  • 3.Vincent AM, Russell JW, Low P, Feldman EL. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev. 2004;25:612–628. doi: 10.1210/er.2003-0019. [DOI] [PubMed] [Google Scholar]
  • 4.Leinninger GM, Edwards JL, Lipshaw MJ, Feldman EL. Mechanisms of disease: mitochondria as new therapeutic targets in diabetic neuropathy. Nat Clin Pract Neurol. 2006;2:620–628. doi: 10.1038/ncpneuro0320. [DOI] [PubMed] [Google Scholar]
  • 5.Tomlinson DR, Gardiner NJ. Glucose neurotoxicity. Nat Rev Neurosci. 2008;9:36–45. doi: 10.1038/nrn2294. [DOI] [PubMed] [Google Scholar]
  • 6.McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. Lancet Neurol. 2005;4:543–555. doi: 10.1016/S1474-4422(05)70165-4. [DOI] [PubMed] [Google Scholar]
  • 7.Childs EA, Lyles RH, Selnes OA, et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology. 1999;52:607–613. doi: 10.1212/wnl.52.3.607. [DOI] [PubMed] [Google Scholar]
  • 8.Tagliati M, Grinnell J, Godbold J, Simpson DM. Peripheral nerve function in HIV infection: clinical, electrophysiologic, and laboratory findings. Arch Neurol. 1999;56:84–89. doi: 10.1001/archneur.56.1.84. [DOI] [PubMed] [Google Scholar]
  • 9.Schifitto G, McDermott MP, McArthur JC, et al. Markers of immune activation and viral load in HIV-associated sensory neuropathy. Neurology. 2005;64:842–848. doi: 10.1212/01.WNL.0000152981.32057.BB. [DOI] [PubMed] [Google Scholar]
  • 10.Lichtenstein KA, Armon C, Baron A, Moorman AC, Wood KC, Holmberg SD, HIV Outpatient Study Investigators Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort. Clin Infect Dis. 2005;40:148–157. doi: 10.1086/426076. [DOI] [PubMed] [Google Scholar]
  • 11.Ferrari S, Vento S, Monaco S, et al. Human immunodeficiency virus-associated peripheral neuropathies. Mayo Clin Proc. 2006;81:213–219. doi: 10.4065/81.2.213. [DOI] [PubMed] [Google Scholar]
  • 12.Pardo CA, McArthur JC, Griffin JW. HIV neuropathy: insights in the pathology of HIV peripheral nerve disease. J Peripher Nerv Syst. 2001;6:21–27. doi: 10.1046/j.1529-8027.2001.006001021.x. [DOI] [PubMed] [Google Scholar]
  • 13.Simpson DM, Kitch D, Evans SR, ACTG A5117 Study Group et al. HIV neuropathy natural history cohort study: assessment measures and risk factors. Neurology. 2006;66:1679–1687. doi: 10.1212/01.wnl.0000218303.48113.5d. [DOI] [PubMed] [Google Scholar]
  • 14.Cherry CL, Skolasky RL, Lal L, et al. Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort. Neurology. 2006;66:867–873. doi: 10.1212/01.wnl.0000203336.12114.09. [DOI] [PubMed] [Google Scholar]
  • 15.Keswani SC, Jack C, Zhou C, Höke A. Establishment of a rodent model of HIV-associated sensory neuropathy. J Neurosci. 2006;26:10299–10304. doi: 10.1523/JNEUROSCI.3135-06.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Pettersen JA, Jones G, Worthington C, et al. Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. Ann Neurol. 2006;59:816–824. doi: 10.1002/ana.20816. [DOI] [PubMed] [Google Scholar]
  • 17.Ellis RJ, Marquie-Beck J, Delaney P, CHARTER Group et al. Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann Neurol. 2008;64:566–572. doi: 10.1002/ana.21484. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Cherry CL, McArthur JC, Hoy JF, Wesselingh SL. Nucleoside analogues and neuropathy in the era of HAART. J Clin Virol. 2003;26:195–207. doi: 10.1016/S1386-6532(02)00118-X. [DOI] [PubMed] [Google Scholar]
  • 19.Dalakas MC, Semino-Mora C, Leon-Monzon M. Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2′3′-dideoxycytidine (ddC) Lab Invest. 2001;81:1537–1544. doi: 10.1038/labinvest.3780367. [DOI] [PubMed] [Google Scholar]
  • 20.Keswani SC, Chander B, Hasan C, Griffin JW, McArthur JC, Hoke A. FK506 is neuroprotective in a model of antiretroviral toxic neuropathy. Ann Neurol. 2003;53:57–64. doi: 10.1002/ana.10401. [DOI] [PubMed] [Google Scholar]
  • 21.Zhu Y, Antony JM, Martinez JA, et al. Didanosine causes sensory neuropathy in an HIV/AIDS animal model: impaired mitochondrial and neurotrophic factor gene expression. Brain. 2007;130:2011–2023. doi: 10.1093/brain/awm148. [DOI] [PubMed] [Google Scholar]
  • 22.Robinson B, Li Z, Nath A. Nucleoside reverse transcriptase inhibitors and human immunodeficiency virus proteins cause axonal injury in human dorsal root ganglia cultures. J Neurovirol. 2007;13:160–167. doi: 10.1080/13550280701200102. [DOI] [PubMed] [Google Scholar]
  • 23.El Idrissi A, Trenkner E. Growth factors and taurine protect against excitotoxicity by stabilizing calcium homeostasis and energy metabolism. J Neurosci. 1999;19:9459–9468. doi: 10.1523/JNEUROSCI.19-21-09459.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Markham A, Cameron I, Franklin P, Spedding M. BDNF increases rat brain mitochondrial respiratory coupling at complex I, but not complex II. Eur J Neurosci. 2004;20:1189–1196. doi: 10.1111/j.1460-9568.2004.03578.x. [DOI] [PubMed] [Google Scholar]
  • 25.Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer. 2008;44:1507–1515. doi: 10.1016/j.ejca.2008.04.018. [DOI] [PubMed] [Google Scholar]
  • 26.Wilkes G. Peripheral neuropathy related to chemotherapy. Semin Oncol Nurs. 2007;23:162–173. doi: 10.1016/j.soncn.2007.05.001. [DOI] [PubMed] [Google Scholar]
  • 27.Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006;33:15–49. doi: 10.1053/j.seminoncol.2005.12.010. [DOI] [PubMed] [Google Scholar]
  • 28.Rao RD, Michalak JC, Sloan JA, North Central Cancer Treatment Group et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3) Cancer. 2007;110:2110–2118. doi: 10.1002/cncr.23008. [DOI] [PubMed] [Google Scholar]
  • 29.McDonald ES, Randon KR, Knight A, Windebank AJ. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol Dis. 2005;18:305–313. doi: 10.1016/j.nbd.2004.09.013. [DOI] [PubMed] [Google Scholar]
  • 30.Scuteri A, Galimberti A, Maggioni D, et al. Role of MAPKs in platinum-induced neuronal apoptosis. Neurotoxicology. 2009;30:312–319. doi: 10.1016/j.neuro.2009.01.003. [DOI] [PubMed] [Google Scholar]
  • 31.James SE, Burden H, Burgess R, et al. Anti-cancer drug induced neurotoxicity and identification of Rho pathway signaling modulators as potential neuroprotectants. Neurotoxicology. 2008;29:605–612. doi: 10.1016/j.neuro.2008.04.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Graham J, Mushin M, Kirkpatrick P. Oxaliplatin. Nat Rev Drug Discov. 2004;3:11–12. doi: 10.1038/nrd1287. [DOI] [PubMed] [Google Scholar]
  • 33.Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol. 2001;85:2293–2297. doi: 10.1152/jn.2001.85.5.2293. [DOI] [PubMed] [Google Scholar]
  • 34.Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A, Eckel F, Lersch C. The chemotherapeutic oxaliplatin alters voltage-gated Na+ channel kinetics on rat sensory neurons. Eur J Pharmacol. 2000;406:25–32. doi: 10.1016/S0014-2999(00)00667-1. [DOI] [PubMed] [Google Scholar]
  • 35.Gamelin L, Capitain O, Morel A, et al. Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin Cancer Res. 2007;13:6359–6368. doi: 10.1158/1078-0432.CCR-07-0660. [DOI] [PubMed] [Google Scholar]
  • 36.Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol. 2002;249:9–17. doi: 10.1007/PL00007853. [DOI] [PubMed] [Google Scholar]
  • 37.Apfel SC, Lipton RB, Arezzo JC, Kessler JA. Nerve growth factor prevents toxic neuropathy in mice. Ann Neurol. 1991;29:87–90. doi: 10.1002/ana.410290115. [DOI] [PubMed] [Google Scholar]
  • 38.Cavaletti G, Cavalletti E, Montaguti P, Oggioni N, De Negri O, Tredici G. Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. Neurotoxicology. 1997;18:137–145. [PubMed] [Google Scholar]
  • 39.Cavaletti G, Tredici G, Braga M, Tazzari S. Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol. Exp Neurol. 1995;133:64–72. doi: 10.1006/exnr.1995.1008. [DOI] [PubMed] [Google Scholar]
  • 40.Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F. Description of a short-term taxol-induced nociceptive neuropathy in rats. Brain Res. 2000;887:239–249. doi: 10.1016/S0006-8993(00)02910-3. [DOI] [PubMed] [Google Scholar]
  • 41.Polomano RC, Mannes AJ, Clark US, Bennett GJ. A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain. 2001;94:293–304. doi: 10.1016/S0304-3959(01)00363-3. [DOI] [PubMed] [Google Scholar]
  • 42.Flatters SJ, Bennett GJ. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain. 2006;122:245–257. doi: 10.1016/j.pain.2006.01.037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Siau C, Xiao W, Bennett GJ. Paclitaxel- and vincristine-evoked painful peripheral neuropathies: loss of epidermal innervation and activation of Langerhans cells. Exp Neurol. 2006;201:507–514. doi: 10.1016/j.expneurol.2006.05.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Thant M, Hawley RJ, Smith MT, et al. Possible enhancement of vincristine neuropathy by VP-16. Cancer. 1982;49:859–864. doi: 10.1002/1097-0142(19820301)49:5<859::AID-CNCR2820490506>3.0.CO;2-9. [DOI] [PubMed] [Google Scholar]
  • 45.Evtodienko YV, Teplova VV, Sidash SS, Ichas F, Mazat JP. Microtubule-active drugs suppress the closure of the permeability transition pore in tumour mitochondria. FEBS Lett. 1996;393:86–88. doi: 10.1016/0014-5793(96)00875-7. [DOI] [PubMed] [Google Scholar]
  • 46.André N, Braguer D, Brasseur G, et al. Paclitaxel induces release of cytochrome c from mitochondria isolated from human neuroblastoma cells. Cancer Res. 2000;60:5349–5353. [PubMed] [Google Scholar]
  • 47.Helgason S, Petursson G, Gudmundsson S, Sigurdsson JA. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. BMJ. 2000;321:794–796. doi: 10.1136/bmj.321.7264.794. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Kost RG, Straus SE. Postherpetic neuralgia: pathogenesis, treatment, and prevention. N Engl J Med. 1996;335:32–42. doi: 10.1056/NEJM199607043350107. [DOI] [PubMed] [Google Scholar]
  • 49.Rowbotham MC, Fields HL. Post-herpetic neuralgia: the relation of pain complaint, sensory disturbance, and skin temperature. Pain. 1989;39:129–144. doi: 10.1016/0304-3959(89)90001-8. [DOI] [PubMed] [Google Scholar]
  • 50.Fields HL, Rowbotham M, Baron R. Postherpetic neuralgia: irritable nociceptors and deafferentation. Neurobiol Dis. 1998;5:209–227. doi: 10.1006/nbdi.1998.0204. [DOI] [PubMed] [Google Scholar]
  • 51.Backonja M, Wallace MS, Blonsky ER, NGX-4010 C116 Study Group et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study [Erratum in: Lancet Neurol 2009;8:31] Lancet Neurol. 2008;7:1106–1112. doi: 10.1016/S1474-4422(08)70228-X. [DOI] [PubMed] [Google Scholar]
  • 52.Christo PJ, Hobelmann G, Maine DN. Post-herpetic neuralgia in older adults: evidence-based approaches to clinical management. Drugs Aging. 2007;24:1–19. doi: 10.2165/00002512-200724010-00001. [DOI] [PubMed] [Google Scholar]
  • 53.Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc. 2009;84:274–280. doi: 10.4065/84.3.274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Osterberg A, Boivie J, Thuomas KA. Central pain in multiple sclerosis: prevalence and clinical characteristics. Eur J Pain. 2005;9:531–542. doi: 10.1016/j.ejpain.2004.11.005. [DOI] [PubMed] [Google Scholar]
  • 55.Boivie J, Leijon G, Johansson I. Central post-stroke pain: a study of the mechanisms through analyses of the sensory abnormalities. Pain. 1989;37:173–185. doi: 10.1016/0304-3959(89)90128-0. [DOI] [PubMed] [Google Scholar]
  • 56.Finnerup NB, Jensen TS. Spinal cord injury pain: mechanisms and treatment. Eur J Neurol. 2004;11:73–82. doi: 10.1046/j.1351-5101.2003.00725.x. [DOI] [PubMed] [Google Scholar]
  • 57.Bowsher D. Central pain: clinical and physiological characteristics. J Neurol Neurosurg Psychiatry. 1996;61:62–69. doi: 10.1136/jnnp.61.1.62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Österberg A, Boivie J. Central pain in multiple sclerosis: sensory abnormalities. Eur J Pain 2009 Apr 8; [Epub ahead of print]. [DOI] [PubMed]
  • 59.Lubetzki C, Williams A, Stankoff B. Promoting repair in multiple sclerosis: problems and prospects. Curr Opin Neurol. 2005;18:237–244. doi: 10.1097/01.wco.0000169739.83793.e0. [DOI] [PubMed] [Google Scholar]
  • 60.Lopez-Diego RS, Weiner HL. Novel therapeutic strategies for multiple sclerosis: a multifaceted adversary. Nat Rev Drug Discov. 2008;7:909–925. doi: 10.1038/nrd2358. [DOI] [PubMed] [Google Scholar]
  • 61.Sah DW, Ossipo MH, Porreca F. Neurotrophic factors as novel therapeutics for neuropathic pain. Nat Rev Drug Discov. 2003;2:460–472. doi: 10.1038/nrd1107. [DOI] [PubMed] [Google Scholar]
  • 62.Wang X, Ratnam J, Zou B, England PM, Basbaum AI. TrkB signaling is required for both the induction and maintenance of tissue and nerve injury-induced persistent pain. J Neurosci. 2009;29:5508–5515. doi: 10.1523/JNEUROSCI.4288-08.2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Hefti FF, Rosenthal A, Walicke PA, et al. Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol Sci. 2006;27:85–91. doi: 10.1016/j.tips.2005.12.001. [DOI] [PubMed] [Google Scholar]
  • 64.Gardell LR, Wang R, Ehrenfels C, et al. Multiple actions of systemic artemin in experimental neuropathy. Nat Med. 2003;9:1383–1389. doi: 10.1038/nm944. [DOI] [PubMed] [Google Scholar]
  • 65.Brenner GJ, Ji RR, Shaffer S, Woolf CJ. Peripheral noxious stimulation induces phosphorylation of the NMDA receptor NR1 subunit at the PKC-dependent site, serine-896, in spinal cord dorsal horn neurons. Eur J Neurosci. 2004;20:375–384. doi: 10.1111/j.1460-9568.2004.03506.x. [DOI] [PubMed] [Google Scholar]
  • 66.Ma QP, Woolf CJ. Noxious stimuli induce an N-methyl-d-aspartate receptor-dependent hypersensitivity of the flexion withdrawal reflex to touch: implications for the treatment of mechanical allodynia. Pain. 1995;61:383–390. doi: 10.1016/0304-3959(94)00195-K. [DOI] [PubMed] [Google Scholar]
  • 67.Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 1997;389:816–824. doi: 10.1038/39807. [DOI] [PubMed] [Google Scholar]
  • 68.Szallasi A, Blumberg PM. Vanilloid (capsaicin) receptors and mechanisms. Pharmacol Rev. 1999;51:159–212. [PubMed] [Google Scholar]
  • 69.Gavva NR, Bannon AW, Surapaneni S, et al. The vanilloid receptor TRPV1 is tonically activated in vivo and involved in body temperature regulation. J Neurosci. 2007;27:3366–3374. doi: 10.1523/JNEUROSCI.4833-06.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Waxman SG, Dib-Hajj S, Cummins TR, Black JA. Sodium channels and pain. Proc Natl Acad Sci U S A. 1999;96:7635–7639. doi: 10.1073/pnas.96.14.7635. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Gold MS, Weinreich D, Kim CS, et al. Redistribution of Nav1.8 in uninjured axons enables neuropathic pain. J Neurosci. 2003;23:158–166. doi: 10.1523/JNEUROSCI.23-01-00158.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Fang X, Djouhri L, McMullan S, et al. trkA is expressed in nociceptive neurons and influences electrophysiological properties via Nav1.8 expression in rapidly conducting nociceptors. J Neurosci. 2005;25:4868–4878. doi: 10.1523/JNEUROSCI.0249-05.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Cox JJ, Reimann F, Nicholas AK, et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature. 2006;444:894–898. doi: 10.1038/nature05413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Fertleman CR, Baker MD, Parker KA, et al. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron. 2006;52:767–774. doi: 10.1016/j.neuron.2006.10.006. [DOI] [PubMed] [Google Scholar]
  • 75.Lai J, Gold MS, Kim CS, et al. Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, Nav1.8. Pain. 2002;95:143–152. doi: 10.1016/S0304-3959(01)00391-8. [DOI] [PubMed] [Google Scholar]
  • 76.Ekberg J, Jayamanne A, Vaughan CW, et al. μO-conotoxin MrVIB selectively blocks Nav1.8 sensory neuron specific sodium channels and chronic pain behavior without motor deficits. Proc Natl Acad Sci U S A. 2006;103:17030–17035. doi: 10.1073/pnas.0601819103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Nassar MA, Stirling LC, Forlani G, et al. Nociceptor-specific gene deletion reveals a major role for Nav1.7 (PN1) in acute and inflammatory pain. Proc Natl Acad Sci U S A. 2004;101:12706–12711. doi: 10.1073/pnas.0404915101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Nassar MA, Levato A, Stirling LC, Wood JN. Neuropathic pain develops normally in mice lacking both Nav1.7 and Nav1.8. Mol Pain. 2005;1:24–24. doi: 10.1186/1744-8069-1-24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Abrahamsen B, Zhao J, Asante CO, et al. The cell and molecular basis of mechanical, cold, and inflammatory pain. Science. 2008;321:702–705. doi: 10.1126/science.1156916. [DOI] [PubMed] [Google Scholar]
  • 80.Waxman SG. Axonal conduction and injury in multiple sclerosis: the role of sodium channels. Nat Rev Neurosci. 2006;7:932–941. doi: 10.1038/nrn2023. [DOI] [PubMed] [Google Scholar]
  • 81.Petronilli V, Costantini P, Scorrano L, Colonna R, Passamonti S, Bemardi P. The voltage sensor of the mitochondrial permeability transition pore is tuned by the oxidation-reduction state of vicinal thiols: increase of the gating potential by oxidants and its reversal by reducing agents. J Biol Chem. 1994;269:16638–16642. [PubMed] [Google Scholar]
  • 82.McStay GP, Clarke SJ, Halestrap AP. Role of critical thiol groups on the matrix surface of the adenine nucleotide translocase in the mechanism of the mitochondrial permeability transition pore. Biochem J. 2002;367:541–548. doi: 10.1042/BJ20011672. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Veenman L, Shandalov Y, Gavish M. VDAC activation by the 18 kDa translocator protein (TSPO), implications for apoptosis. J Bioenerg Biomembr. 2008;40:199–205. doi: 10.1007/s10863-008-9142-1. [DOI] [PubMed] [Google Scholar]
  • 84.Leung AW, Halestrap AP. Recent progress in elucidating the molecular mechanism of the mitochondrial permeability transition pore. Biochim Biophys Acta. 2008;1777:946–952. doi: 10.1016/j.bbabio.2008.03.009. [DOI] [PubMed] [Google Scholar]
  • 85.Pastorino JG, Hoek JB. Regulation of hexokinase binding to VDAC. J Bioenerg Biomembr. 2008;40:171–182. doi: 10.1007/s10863-008-9148-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Carré M, André N, Carles G, et al. Tubulin is an inherent component of mitochondrial membranes that interacts with the voltage-dependent anion channel. J Biol Chem. 2002;277:33664–33669. doi: 10.1074/jbc.M203834200. [DOI] [PubMed] [Google Scholar]
  • 87.Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science. 2005;307:384–387. doi: 10.1126/science.1104343. [DOI] [PubMed] [Google Scholar]
  • 88.Leinninger GM, Backus C, Sastry AM, Yi YB, Wang CW, Feldman EL. Mitochondria in DRG neurons undergo hyperglycemic mediated injury through Bim, Bax and the fission protein Drpl. Neurobiol Dis. 2006;23:11–22. doi: 10.1016/j.nbd.2006.01.017. [DOI] [PubMed] [Google Scholar]
  • 89.Siau C, Bennett GJ. Dysregulation of cellular calcium homeostasis in chemotherapy-evoked painful peripheral neuropathy. Anesth Analg. 2006;102:1485–1490. doi: 10.1213/01.ane.0000204318.35194.ed. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Shu XQ, Mendell LM. Neurotrophins and hyperalgesia. Proc Natl Acad Sci U S A. 1999;96:7693–7696. doi: 10.1073/pnas.96.14.7693. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91.Ogun-Muyiwa P, Helliwell R, McIntyre P, Winter J. Glial cell line derived neurotrophic factor (GDNF) regulates VR1 and substance P in cultured sensory neurons. Neuroreport. 1999;10:2107–2111. doi: 10.1097/00001756-199907130-00021. [DOI] [PubMed] [Google Scholar]
  • 92.Hudson LJ, Bevan S, Wotherspoon G, Gentry C, Fox A, Winter J. VR1 protein expression increases in undamaged DRG neurons after partial nerve injury. Eur J Neurosci. 2001;13:2105–2114. doi: 10.1046/j.0953-816x.2001.01591.x. [DOI] [PubMed] [Google Scholar]
  • 93.Zhang XF, Zhu CZ, Thimmapaya R, et al. Differential action potentials and firing patterns in injured and uninjured small dorsal root ganglion neurons after nerve injury. Brain Res. 2004;1009:147–158. doi: 10.1016/j.brainres.2004.02.057. [DOI] [PubMed] [Google Scholar]
  • 94.Mansour HH. Protective role of camitine ester against radiation-induced oxidative stress in rats. Pharmacol Res. 2006;54:165–171. doi: 10.1016/j.phrs.2006.04.003. [DOI] [PubMed] [Google Scholar]
  • 95.Ferraresi R, Troiano L, Roat E, et al. Protective effect of acetyl-l-carnitine against oxidative stress induced by antiretroviral drugs. FEBS Lett. 2006;580:6612–6616. doi: 10.1016/j.febslet.2006.11.016. [DOI] [PubMed] [Google Scholar]
  • 96.Manfridi A, Forloni GL, Arrigoni-Martelli E, Mancia M. Culture of dorsal root ganglion neurons from aged rats: effects of acetyl-lL-carnitine and NGF. Int J Dev Neurosci. 1992;10:321–329. doi: 10.1016/0736-5748(92)90021-Q. [DOI] [PubMed] [Google Scholar]
  • 97.Liu J, Killilea DW, Ames BN. Age-associated mitochondrial oxidative decay: improvement of carnitine acetyltransferase substrate-binding affinity and activity in brain by feeding old rats acetyl-l-carnitine and/or R-α-lipoic acid [Erratum in: Proc Natl Acad Sci U S A 2002;99:7184] Proc Natl Acad Sci U S A. 2002;99:1876–1881. doi: 10.1073/pnas.261709098. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98.Picconi B, Barone I, Pisani A, et al. Acetyl-l-carnitine protects striatal neurons against in vitro ischemia: the role of endogenous acetylcholine. Neuropharmacology. 2006;50:917–923. doi: 10.1016/j.neuropharm.2006.01.002. [DOI] [PubMed] [Google Scholar]
  • 99.Alves E, Binienda Z, Carvalho F, et al. Acetyl-l-carnitine provides effective in vivo neuroprotection over 3,4-methylenedioximethamphetamine-induced mitochondrial neurotoxicity in the adolescent rat brain. Neuroscience. 2009;158:514–523. doi: 10.1016/j.neuroscience.2008.10.041. [DOI] [PubMed] [Google Scholar]
  • 100.Fernandez E, Pallini R, Gangitano C, et al. Effects of l-carnitine, l-acetylcarnitine and gangliosides on the regeneration of the transected sciatic nerve in rats. Neurol Res. 1989;11:57–62. doi: 10.1080/01616412.1989.11739863. [DOI] [PubMed] [Google Scholar]
  • 101.Mamoulakis D, Galanakis E, Dionyssopoulou E, Evangeliou A, Sbyrakis S. Camitine deficiency in children and adolescents with type 1 diabetes. J Diabetes Complications. 2004;18:271–274. doi: 10.1016/S1056-8727(03)00091-6. [DOI] [PubMed] [Google Scholar]
  • 102.Famularo G, Moretti S, Marcellini S, et al. Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues. AIDS. 1997;11:185–190. doi: 10.1097/00002030-199702000-00008. [DOI] [PubMed] [Google Scholar]
  • 103.Ido Y, McHowat J, Chang KC, et al. Neural dysfunction and metabolic imbalances in diabetic rats: prevention by acetyl-l-carnitine. Diabetes. 1994;43:1469–1477. doi: 10.2337/diabetes.43.12.1469. [DOI] [PubMed] [Google Scholar]
  • 104.Lowitt S, Malone JI, Salem AF, Korthals J, Benford S. Acetyl-l-carnitine corrects the altered peripheral nerve function of experimental diabetes. Metabolism. 1995;44:677–680. doi: 10.1016/0026-0495(95)90128-0. [DOI] [PubMed] [Google Scholar]
  • 105.Nakamura J, Koh N, Sakakibara F, et al. Polyol pathway hyperactivity is closely related to carnitine deficiency in the pathogenesis of diabetic neuropathy of streptozotocin-diabetic rats. J Pharmacol Exp Ther. 1998;287:897–902. [PubMed] [Google Scholar]
  • 106.Stevens MJ, Lattimer SA, Feldman EL, et al. Acetyl-l-carnitine deficiency as a cause of altered nerve myo-inositol content, Na,K-ATPase activity, and motor conduction velocity in the streptozotocin-diabetic rat. Metabolism. 1996;45:865–872. doi: 10.1016/S0026-0495(96)90161-4. [DOI] [PubMed] [Google Scholar]
  • 107.Sima AA, Ristic H, Merry A, et al. Primary preventive and secondary interventionary effects of acetyl-l-carnitine on diabetic neuropathy in the bio-breeding Worcester rat. J Clin Invest. 1996;97:1900–1907. doi: 10.1172/JCI118621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108.Ohsawa M, Miyata S, Carlsson A, Kamei J. Preventive effect of acetyl-l-carnitine on the thermal hypoalgesia in streptozotocin-induced diabetic mice. Eur J Pharmacol. 2008;588:213–216. doi: 10.1016/j.ejphar.2008.04.029. [DOI] [PubMed] [Google Scholar]
  • 109.Pisano C, Pratesi G, Laccabue D, et al. Paclitaxel and cisplatin-induced neurotoxicity: a protective role of acetyl-l-carnitine. Clin Cancer Res. 2003;9:5756–5767. [PubMed] [Google Scholar]
  • 110.Ghirardi O, Lo Giudice P, Pisano C, et al. Acetyl-l-carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties. Anticancer Res. 2005;25:2681–2687. [PubMed] [Google Scholar]
  • 111.Flatters SJ, Xiao WH, Bennett GJ. Acetyl-l-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy. Neurosci Lett. 2006;397:219–223. doi: 10.1016/j.neulet.2005.12.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 112.Xiao W, Bennett GJ. Chemotherapy-evoked neuropathic pain: abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by acetyl-l-carnitine. Pain. 2008;135:262–270. doi: 10.1016/j.pain.2007.06.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113.Piovesan P, Pacifici L, Taglialatela G, Ramacci MT, Angelucci L. Acetyl-l-carnitine treatment increases choline acetyltransferase activity and NGF levels in the CNS of adult rats following total fimbria-fornix transection. Brain Res. 1994;633:77–82. doi: 10.1016/0006-8993(94)91524-5. [DOI] [PubMed] [Google Scholar]
  • 114.Foreman PJ, Perez-Polo JR, Angelucci L, Ramacci MT, Taglialatela G. Effects of acetyl-l-carnitine treatment and stress exposure on the nerve growth factor receptor (p75NGFR) mRNA level in the central nervous system of aged rats. Prog Neuropsychopharmacol Biol Psychiatry. 1995;19:117–133. doi: 10.1016/0278-5846(94)00109-U. [DOI] [PubMed] [Google Scholar]
  • 115.Barhwal K, Hota SK, Prasad D, Singh SB, Ilavazhagan G. Hypoxia-induced deactivation of NGF-mediated ERK1/2 signaling in hippocampal cells: neuroprotection by acetyl-l-carnitine. J Neurosci Res. 2008;86:2705–2721. doi: 10.1002/jnr.21722. [DOI] [PubMed] [Google Scholar]
  • 116.Di Cesare Mannelli L, Ghelardini C, Calvani M, et al. Protective effect of acetyl-l-carnitine on the apoptotic pathway of peripheral neuropathy. Eur J Neurosci. 2007;26:820–827. doi: 10.1111/j.1460-9568.2007.05722.x. [DOI] [PubMed] [Google Scholar]
  • 117.Pettegrew JW, Levine J, McClure RJ. Acetyl-l-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer’s disease and geriatric depression. Mol Psychiatry. 2000;5:616–632. doi: 10.1038/sj.mp.4000805. [DOI] [PubMed] [Google Scholar]
  • 118.Jin HW, Flatters SJ, Xiao WH, Mulhern HL, Bennett GJ. Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-l-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. Exp Neurol. 2008;210:229–237. doi: 10.1016/j.expneurol.2007.11.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 119.Chiechio S, Caricasole A, Barletta E, et al. l-Acetylcarnitine induces analgesia by selectively up-regulating mGlu2 metabotropic glutamate receptors. Mol Pharmacol. 2002;61:989–996. doi: 10.1124/mol.61.5.989. [DOI] [PubMed] [Google Scholar]
  • 120.Chiechio S, Copani A, De Petris L, Morales ME, Nicoletti F, Gereau RW. Transcriptional regulation of metabotropic glutamate receptor 2/3 expression by the NF-κB pathway in primary dorsal root ganglia neurons: a possible mechanism for the analgesic effect of l-acetylcarnitine. Mol Pain. 2006;2:20–20. doi: 10.1186/1744-8069-2-20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 121.Ghelardini C, Galeotti N, Calvani M, Mosconi L, Nicolai R, Bartolini A. Acetyl-l-carnitine induces muscarinic antinociception in mice and rats. Neuropharmacology. 2002;43:1180–1187. doi: 10.1016/S0028-3908(02)00225-3. [DOI] [PubMed] [Google Scholar]
  • 122.Di Cesare Mannelli L, Ghelardini C, Calvani M, et al. Neuroprotective effects of acetyl-l-carnitine on neuropathic pain and apoptosis: a role for the nicotinic receptor. J Neurosci Res. 2009;87:200–207. doi: 10.1002/jnr.21815. [DOI] [PubMed] [Google Scholar]
  • 123.Grandis DD. Tolerability and efficacy of l-acetylcarnitine in patients with peripheral neuropathies: a short-term, open multicentre study. Clin Drug Investig. 1998;15:73–79. doi: 10.2165/00044011-199815020-00001. [DOI] [PubMed] [Google Scholar]
  • 124.Evans JD, Jacobs TF, Evans EW. Role of acetyl-l-carnitine in the treatment of diabetic peripheral neuropathy. Ann Pharmacother. 2008;42:1686–1691. doi: 10.1345/aph.1L201. [DOI] [PubMed] [Google Scholar]
  • 125.Sima AA, Calvani M, Mehra M, Amato A, Acetyl-l-Camitine Study Group Acetyl-l-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. Diabetes Care. 2005;28:89–94. doi: 10.2337/diacare.28.1.89. [DOI] [PubMed] [Google Scholar]
  • 126.Bianchi G, Vitali G, Caraceni A, et al. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-l-carnitine. Eur J Cancer. 2005;41:1746–1750. doi: 10.1016/j.ejca.2005.04.028. [DOI] [PubMed] [Google Scholar]
  • 127.Maestri A, De Pasquale Ceratti A, Cundari S, Zanna C, Cortesi E, Crinò L. A pilot study on the effect of acetyl-l-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. Tumori. 2005;91:135–138. doi: 10.1177/030089160509100206. [DOI] [PubMed] [Google Scholar]
  • 128.Hart AM, Wilson AD, Montovani C, et al. Acetyl-l-carnitine: a pathogenesis based treatment for HIV-associated antiretroviral toxic neuropathy. AIDS. 2004;18:1549–1560. doi: 10.1097/01.aids.0000131354.14408.fb. [DOI] [PubMed] [Google Scholar]
  • 129.Herzmann C, Johnson MA, Youle M. Long-term effect of acetyl-l-carnitine for antiretroviral toxic neuropathy. HIV Clin Trials. 2005;6:344–350. doi: 10.1310/CH1N-YBNU-G3CU-JBXR. [DOI] [PubMed] [Google Scholar]
  • 130.Valcour V, Yeh TM, Bartt R, et al. Acetyl-l-carnitine and nucleoside reverse transcriptase inhibitor-associated neuropathy in HIV infection. HIV Med. 2009;10:103–110. doi: 10.1111/j.1468-1293.2008.00658.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 131.Bordet T, Buisson B, Michaud M, et al. Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J Pharmacol Exp Ther. 2007;322:709–720. doi: 10.1124/jpet.107.123000. [DOI] [PubMed] [Google Scholar]
  • 132.Rostovtseva TK, Sheldon KL, Hassanzadeh E, et al. Tubulin binding blocks mitochondrial voltage-dependent anion channel and regulates respiration. Proc Natl Acad Sci U S A. 2008;105:18746–18751. doi: 10.1073/pnas.0806303105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 133.Bordet T, Buisson B, Michaud M, et al. Specific antinociceptive activity of cholest-4-en-3-one, oxime (TRO19622) in experimental models of painful diabetic and chemotherapy-induced neuropathy. J Pharmacol Exp Ther. 2008;326:623–632. doi: 10.1124/jpet.108.139410. [DOI] [PubMed] [Google Scholar]
  • 134.Pabbidi RM, Cao DS, Parihar A, Pauza ME, Premkumar LS. Direct role of streptozotocin in inducing thermal hyperalgesia by enhanced expression of transient receptor potential vanilloid 1 in sensory neurons. Mol Pharmacol. 2008;73:995–1004. doi: 10.1124/mol.107.041707. [DOI] [PubMed] [Google Scholar]
  • 135.Simiand J, Keane PE, Barnouin MC, Keane M, Soubrié P, Le Fur G. Neuropsychopharmacological profile in rodents of SR 57746A, a new, potent 5-HT1A receptor agonist. Fundam Clin Pharmacol. 1993;7:413–427. [PubMed] [Google Scholar]
  • 136.Labie C, Lafon C, Marmouget C, et al. Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex. Br J Pharmacol. 1999;127:139–144. doi: 10.1038/sj.bjp.0702545. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 137.Fournier J, Steinberg R, Gauthier T, et al. Protective effects of SR 57746A in central and peripheral models of neurodegenerative disorders in rodents and primates. Neuroscience. 1993;55:629–641. doi: 10.1016/0306-4522(93)90429-J. [DOI] [PubMed] [Google Scholar]
  • 138.Cassidy J, Bjamason GA, Hickish T. Randomized double blind (DB) placebo (Plcb) controlled phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in firstline treatment of patients (pts) with metastatic colorectal cancer (MCRC) J Clin Oncol. 2006;24(Suppl 18S):3507–3507. [Google Scholar]
  • 139.Susman E. Xaliproden lessens oxaliplatin-mediated neuropathy. Lancet Oncol. 2006;7:288–288. doi: 10.1016/S1470-2045(06)70639-8. [DOI] [PubMed] [Google Scholar]
  • 140.Kakinoki B, Sekimoto S, Yuki S, et al. Orally active neurotrophin-enhancing agent protects against dysfunctions of the peripheral nerves in hyperglycemic animals. Diabetes. 2006;55:616–621. doi: 10.2337/diabetes.55.03.06.db05-1091. [DOI] [PubMed] [Google Scholar]
  • 141.Calcutt NA, Freshwater JD, Hauptmann N, Taylor EM, Mizisin AP. Protection of sensory function in diabetic rats by Neotrofin. Eur J Pharmacol. 2006;534:187–193. doi: 10.1016/j.ejphar.2006.01.047. [DOI] [PubMed] [Google Scholar]
  • 142.Gavish M, Bachman I, Shoukrun R, et al. Enigma of the peripheral benzodiazepine receptor. Pharmacol Rev. 1999;51:629–650. [PubMed] [Google Scholar]
  • 143.Galiegue S, Tinel N, Casellas P. The peripheral benzodiazepine receptor: a promising therapeutic drug target. Curr Med Chem. 2003;10:1563–1572. doi: 10.2174/0929867033457223. [DOI] [PubMed] [Google Scholar]
  • 144.Veenman L, Papadopoulos V, Gavish M. Channel-like functions of the 18-kDa translocator protein (TSPO): regulation of apoptosis and steroidogenesis as part of the host-defense response. Curr Pharm Des. 2007;13:2385–2405. doi: 10.2174/138161207781368710. [DOI] [PubMed] [Google Scholar]
  • 145.Vin V, Leducq N, Bono F, Herbert JM. Binding characteristics of SSR180575, a potent and selective peripheral benzodiazepine ligand. Biochem Biophys Res Commun. 2003;310:785–790. doi: 10.1016/j.bbrc.2003.09.079. [DOI] [PubMed] [Google Scholar]
  • 146.Ferzaz B, Brault E, Bourliaud G, et al. SSR180575 (7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide), a peripheral benzodiazepine receptor ligand, promotes neuronal survival and repair. J Pharmacol Exp Ther. 2002;301:1067–1078. doi: 10.1124/jpet.301.3.1067. [DOI] [PubMed] [Google Scholar]
  • 147.Gibson GE, Karuppagounder SS, Shi Q. Oxidant-induced changes in mitochondria and calcium dynamics in the pathophysiology of Alzheimer’s disease. Ann N Y Acad Sci. 2008;1147:221–232. doi: 10.1196/annals.1427.038. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 148.Apfel SC, Schwartz S, Adornato BT, rhNGF Clinical Investigator Group et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. JAMA. 2000;284:2215–2221. doi: 10.1001/jama.284.17.2215. [DOI] [PubMed] [Google Scholar]
  • 149.Schifitto G, Yiannoutsos C, Simpson DM, AIDS Clinical Trials Group Team 291 et al. Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy. Neurology. 2001;57:1313–1316. doi: 10.1212/wnl.57.7.1313. [DOI] [PubMed] [Google Scholar]
  • 150.Wellmer A, Misra VP, Sharief MK, Kopelman PG, Anand P. A double-blind placebo-controlled clinical trial of recombinant human brain-derived neurotrophic factor (rhBDNF) in diabetic polyneuropathy. J Peripher Nerv Syst. 2001;6:204–210. doi: 10.1046/j.1529-8027.2001.01019.x. [DOI] [PubMed] [Google Scholar]
  • 151.Evans SR, Simpson DM, Kitch DW, et al. A randomized trial evaluating Prosaptide for HIV-associated sensory neuropathies: use of an electronic diary to record neuropathic pain. PLoS One. 2007;2:e551–e551. doi: 10.1371/journal.pone.0000551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 152.Reljanovic M, Reichel G, Rett K, et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (α-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res. 1999;31:171–179. doi: 10.1080/10715769900300721. [DOI] [PubMed] [Google Scholar]
  • 153.Ziegler D, Ametov A, Barinov A, et al. Oral treatment with α-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006;29:2365–2370. doi: 10.2337/dc06-1216. [DOI] [PubMed] [Google Scholar]

Articles from Neurotherapeutics are provided here courtesy of Elsevier

RESOURCES